Exclusive: AI startup Chai lands GSK deal, its sixth pharma partner in nine months
Artificial intelligence startup Chai Discovery has signed a collaboration agreement with GSK, making the drugmaker its sixth pharmaceutical partner in nine months. The partnership follows a successful wet-lab evaluation of Chai Discovery's AI models. The startup focuses on developing advanced technology for biological discovery and drug development. Pharmaceutical companies increasingly turn to artificial intelligence tools to accelerate research and development pipelines. This deal expands the startup's industry footprint as major drugmakers test computational biology applications against physical laboratory results. Both companies confirmed the collaboration following the completion of the evaluation phase.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ Chai Discovery has secured a partnership with GSK.
- ✓ GSK is Chai Discovery's sixth pharmaceutical partner in nine months.
- ✓ The collaboration follows a successful wet-lab evaluation of the startup's AI models.
What changed
Chai Discovery added GSK to its roster of pharmaceutical partners following a successful wet-lab evaluation.
Live updates
-
AI startup Chai secures GSK partnership for biological models
Artificial intelligence startup Chai Discovery has signed a collaboration agreement with GSK, making the drugmaker its sixth pharmaceutical partner in nine months. The partnership follows a successful wet-lab evaluation of Chai Discovery's AI models. The startup focuses on developing advanced technology for biological discovery and drug development. Pharmaceutical companies increasingly turn to artificial intelligence tools to accelerate research and development pipelines. This deal expands the startup's industry footprint as major drugmakers test computational biology applications against physical laboratory results. Both companies confirmed the collaboration following the completion of the evaluation phase.
Why it matters
Pharmaceutical companies routinely evaluate artificial intelligence platforms in physical laboratories before committing to commercial partnerships. Chai Discovery has rapidly scaled its business by securing multiple industry agreements within a brief operating window. These collaborations reflect broader industry investments in machine learning models designed to predict molecular structures and interactions.
What is confirmed
- Chai Discovery has secured a partnership with GSK.
- GSK is Chai Discovery's sixth pharmaceutical partner in nine months.
- The collaboration follows a successful wet-lab evaluation of the startup's AI models.
What to watch next
- Further announcements regarding joint drug discovery pipelines between Chai Discovery and its pharmaceutical partners.
- Additional performance data from wet-lab evaluations of AI biological models.
confidence 100%Sources used for this update (12)
- Endpoints News — Exclusive: AI startup Chai lands GSK deal, its sixth pharma partner in nine months
- Fierce Biotech — GSK drinks in Chai Discovery’s AI models after wet-lab validation
- Business Wire — Chai Discovery Announces Collaboration with GSK Following Successful Wet-Lab Evaluation
- FirstWord Pharma — Chai adds GSK to its roster of pharma deals after positive lab tests
- Contract Pharma — Chai Discovery, GSK Announce Collaboration Following Wet-Lab Evaluation
- explore.ghost.org — Wheelchair Travel - Ghost Explore
- explore.ghost.org — Wheel the World - Ghost Explore
- explore.ghost.org — Payment & Banking - Ghost Explore
- explore.ghost.org — Low Vision Guide - Ghost Explore
- explore.ghost.org — Aktienbeobachter - Ghost Explore
- explore.ghost.org — Seedbutler - Ghost Explore
- explore.ghost.org — Was Bitcoin bringt. - Ghost Explore
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community